AxoGen Inc. (NASDAQ:AXGN)‘s stock had its “outperform” rating reiterated by stock analysts at Wedbush in a research note issued to investors on Friday. They currently have a $12.00 price target on the stock. Wedbush’s price objective indicates a potential upside of 36.36% from the company’s current price.
A number of other equities research analysts have also issued reports on the company. JMP Securities reiterated a “buy” rating on shares of AxoGen in a research note on Tuesday. Lake Street Capital lowered AxoGen from a “buy” rating to a “hold” rating and set a $9.00 price target for the company. in a research note on Thursday, November 3rd.
AxoGen (NASDAQ:AXGN) traded up 0.57% during midday trading on Friday, hitting $8.80. The stock had a trading volume of 111,646 shares. AxoGen has a 1-year low of $4.52 and a 1-year high of $9.88. The stock’s 50-day moving average is $8.66 and its 200-day moving average is $7.64. The company’s market capitalization is $289.50 million.
AxoGen (NASDAQ:AXGN) last announced its earnings results on Wednesday, November 2nd. The company reported ($0.08) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.08). AxoGen had a negative return on equity of 292.94% and a negative net margin of 33.02%. Equities research analysts forecast that AxoGen will post ($0.38) EPS for the current year.
In other news, Director Amy Mcbride Wendell acquired 13,333 shares of the business’s stock in a transaction dated Friday, October 7th. The stock was purchased at an average price of $7.50 per share, for a total transaction of $99,997.50. Following the completion of the transaction, the director now directly owns 13,333 shares in the company, valued at approximately $99,997.50. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, CEO Karen L. Zaderej acquired 10,000 shares of the business’s stock in a transaction dated Friday, October 7th. The shares were purchased at an average price of $7.50 per share, with a total value of $75,000.00. Following the transaction, the chief executive officer now owns 242,147 shares of the company’s stock, valued at $1,816,102.50. The disclosure for this purchase can be found here. Insiders own 9.33% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Summit Partners Public Asset Management LLC purchased a new position in shares of AxoGen during the third quarter worth $2,376,000. The Manufacturers Life Insurance Company purchased a new position in shares of AxoGen during the third quarter worth $165,000. Analytic Investors LLC purchased a new position in shares of AxoGen during the third quarter worth $1,763,000. Two Sigma Advisers LP purchased a new position in shares of AxoGen during the third quarter worth $243,000. Finally, Susquehanna International Group LLP purchased a new position in shares of AxoGen during the third quarter worth $112,000. Hedge funds and other institutional investors own 54.43% of the company’s stock.